3482-49-3 Usage
Uses
Used in Pharmaceutical Industry:
Fusidine is used as an antibiotic for its bacteriostatic properties, particularly effective against gram-positive bacteria. It functions by inhibiting the ribosome-dependent activity of the G factor and the translocation of peptidyl-tRNA, thus suppressing protein synthesis in prokaryotes.
Used in Pancreatic Islet Cell Protection:
Fusidine is used as a protective agent for pancreatic islet cells, as it has been shown to suppress nitric oxide lysis, which can lead to cell damage or death.
Additionally, while not explicitly mentioned in the provided materials, fusidine may also have potential applications in research and development due to its unique mechanism of action and ability to inhibit specific cellular processes. This could include uses in studying protein synthesis, ribosome function, and the development of new antibiotics or therapies targeting gram-positive bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 3482-49-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,8 and 2 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3482-49:
(6*3)+(5*4)+(4*8)+(3*2)+(2*4)+(1*9)=93
93 % 10 = 3
So 3482-49-3 is a valid CAS Registry Number.
3482-49-3Relevant academic research and scientific papers
Fusidic acid ring B hydroxylation by Cunninghamella elegans
Ibrahim, Abdel-Rahim S.,Ragab, Amany E.
, p. 86 - 89 (2018/04/14)
Fusidic acid (1) biotransformation using the fungus Cunninghamella elegans NRRL 1392 was studied. Two hydroxylated derivatives of fusidic acid (2, 3) were isolated, and their structures were fully elucidated using various spectroscopic techniques includin
PREPARATION OF A CRYSTALLINE ANTIBIOTIC SUBSTANCE
-
Page/Page column 33-34, (2008/06/13)
The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.
Glycosylated analogs of fusidic acid
-
, (2008/06/13)
Novel analogs of fusidic acid are described with one or more carbohydrate units attached. Certain glycosylated analogs of fusidic acid have enhanced solubility properties in diluents or excipient of choice as compared to unmodified fusidic acid. Certain glycosylated analogs may be employed as chemotherapeutic agents and particular analogs may be useful for fighting anti-microbial infections.
